Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells

Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) is a leading asexual blood-stage vaccine candidate for malaria. In preparation for clinical trials, a full-length PfRH5 protein vaccine called “RH5.1” was produced as a soluble product under cGMP using the ExpreS2 platform (based o...

Full description

Bibliographic Details
Main Authors:	Jin, J, Tarrant, R, Bolam, E, Angell-Manning, P, Soegaard, M, Pattinson, D, Dulal, P, Silk, S, Marshall, J, Dabbs, R, Nugent, F, Barrett, J, Hjerrild, K, Poulsen, L, Jørgensen, T, Brenner, T, Baleanu, I, Parracho, H, Tahiri-Alaoui, A, Whale, G, Moyle, S, Payne, R, Minassian, A, Higgins, M, Detmers, F, Lawrie, A, Douglas, A, Smith, R, De Jongh, W, Berrie, E, Ashfield, R, Draper, S
Format:	Journal article
Language:	English
Published:	Nature Publishing Group 2018

Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells

Similar Items